| Total | 2D TRUS | 3D TRUS | P value |
---|---|---|---|---|
Whole group (1339 patients) | ||||
Number of biopsy sessions | N = 1618 | N = 1149 (71.0%) | N = 469 (29.0%) |  |
Age in years, mean (SD) | 63.4 (SD: 6.30) | 63.0 (SD: 6.27) | 64.6 (SD: 6.24) | < 0.001 |
PSA in ng/mL, mean (SD) | 6.92 (SD: 1.84) | 6.95 (SD: 1.85) | 6.84 (SD: 1.84) | 0.248 |
DRE: | ||||
 • benign, n (%) | 1028 (68.3%) | 739 (69.3%) | 289 (65.7%) | 0.167 |
 • suspicious, n (%) | 478 (31.7%) | 327 (30.7%) | 151 (34.3%) |  |
Prostate volume in ml, median (IQR) | 41 (30–56) | 40 (30–54) | 46 (33–63) | < 0.001 |
Type of biopsy sessions: | ||||
 • Biopsy naive, n (%) | 1238 (76.5%) | 863 (75.1%) | 375 (80.0%) | 0.037 |
 • Prior negative, n (%) | 380 (23.5%) | 286 (24.9%) | 94 (20.0%) |  |
Type of operator: | ||||
 • Experienced, n (%) | 843 (52.1%) | 498 (43.3%) | 345 (73.6%) | <  0.001 |
 • Less experienced, n (%) | 775 (47.9%) | 651 (56.7%) | 124 (26.4%) |  |
Biopsy cores per session, mean (SD) | 12.3 (SD 1.04) | 12.3 (SD 1.05) | 12.3 (SD 1.02) | 0.555 |
Biopsy sessions with fragmentation, n (%) | 442 (27.3%) | 433 (37.7%) | 9 (1.9%) | < 0.001 |
Length of biopsy cores in mm, mean (SD)a | 13.84 (SD: 2.98) | 12.38 (SD: 2.82) | 16.08 (SD: 1.41) | < 0.001 |
Biopsy naïve group (1238 patients) | ||||
Number of biopsy sessions | N = 1238 | N = 863 (69.7%) | N = 375 (30.3%) |  |
Age in years, mean (SD) | 63.5 (SD: 6.46) | 63.0 (SD: 6.43) | 64.7 (SD: 6.35) | < 0.001 |
PSA in ng/mL, mean (SD) | 6.73 (SD: 1.87) | 6.72 (SD: 1.87) | 6.74 (SD: 1.86) | 0.877 |
DRE: | ||||
 • benign, n (%) | 777 (66.9%) | 556 (68.6%) | 221 (63.0%) | 0.063 |
 • suspicious, n (%) | 385 (33.1%) | 255 (31.4%) | 130 (37.0%) |  |
Prostate volume in ml, median (IQR) | 40 (30–55) | 40 (29–52) | 44 (32–60) | < 0.001 |
Type of operator: | ||||
• Experienced, n (%) | 643 (51.9%) | 368 (42.6%) | 275 (73.3%) | < 0.001 |
• Less experienced, n (%) | 595 (48.1%) | 495 (57.4%) | 100 (26.7%) |  |
Biopsy cores per session, mean (SD) | 12.2 (SD 0.79) | 12.2 (SD 0.80) | 12.2 (SD 0.77) | 0.779 |
Biopsy sessions with fragmentation, n (%) | 334 (27.0%) | 325 (37.7%) | 9 (2.4%) | < 0.001 |
Length of biopsy cores in mm, mean (SD)a | 13.84 (SD: 2.96) | 12.33 (SD: 2.78) | 16.07 (SD: 1.40) | < 0.001 |
Prior negative group (321 patients) | ||||
Number of biopsy sessions | N = 380 | N = 286 (75.3%) | N = 94 (24.7%) |  |
Prior negative sessions specified: | ||||
 • Second session | 300 (78.9%) | 225 (78.7%) | 75 (79.8%) | 0.658 |
 • Third session | 64 (16.8%) | 47 (16.4%) | 17 (18.1%) |  |
 • Fourth session | 14 (3.7%) | 12 (4.2%) | 2 (2.1%) |  |
 • Fifth session | 2 (0.5%) | 2 (0.7%) | 0 |  |
Age in years, mean (SD) | 63.1 (SD: 5.79) | 62.8 (SD: 5.80) | 63.9 (SD: 5.73) | 0.135 |
PSA in ng/mL, mean (SD) | 7.54 (SD: 1.60) | 7.65 (SD: 1.54) | 7.20 (SD: 1.73) | 0.023 |
DRE: | ||||
 • benign, n (%) | 251 (73.0%) | 183 (71.8%) | 68 (76.4%) | 0.396 |
 • suspicious, n (%) | 93 (27.0%) | 72 (28.2%) | 21 (23.6%) |  |
Prostate volume in ml, median (IQR) | 46 (32–62) | 44 (31–58) | 54 (39–70) | < 0.001 |
Type of operator: | ||||
 • Experienced, n (%) | 200 (52.6%) | 130 (45.5%) | 70 (74.5%) | < 0.001 |
 • Less experienced, n (%) | 180 (47.4%) | 156 (54.5%) | 24 (25.5%) |  |
Biopsy cores per session, mean (SD) | 12.6 (SD 1.56) | 12.7 (SD 1.53) | 12.6 (SD 1.67) | 0.519 |
Biopsy sessions with fragmentation, n (%) | 113 (29.7%) | 113 (39.2%) | 0 | < 0.001 |
Length of biopsy cores in mm, mean (SD)a | 13.81 (SD: 3.05) | 12.54 (SD: 2.96) | 16.10 (SD: 1.48) | < 0.001 |